| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.gtbl.in | |
| Financial Indicators | ||
|---|---|---|
| Market Cap | 586.31 Cr. | |
| Earnings per share (EPS) | 20.77 | Trailing Twelve Months Ending 2021-03 |
| Price-Earning Ratio (PE) | 19.43 | Trailing Twelve Months Ending 2021-03 |
| Industry PE | 32.66 | Trailing Twelve Months Ending 2021-03 |
| Book Value / Share | 48.14 | Trailing Twelve Months Ending 2021-03 |
| Price to Book Value | 8.38 | Calculated using Price: 403.55 |
| Dividend Yield | 0.41 | Period Ending 2020-03 |
| No. of Shares Subscribed | 1.45 Cr. | 14,528,702 Shares |
| FaceValue | 5 | |
| Company Profile | ||
|
Gujarat Themis Biosyn Ltd, established in 1981, is a biotech and synthetic product manufacturing company, having plants at Vapi, Hyderabad, with group turnover of over $ 40 million. It has EDMFs, available and WHO approved plants. The company has world-wide exports to satisfied customers, having customised facility for all products. The company’s principal activity is to manufacture and distributes pharmaceuticals bulk drugs called rifampicin produced by fermentation process. The company's products include preparations of active pharmaceutical ingredient rifampicin and lovastatin. The company exports its products to Europe and the United States. Kopran alongwith Cadila Healthcare Ltd., Lyka Labs Ltd., Themis Chemicals Ltd. and Anant & Co., formed Pharmaceutical Business Group (India) Ltd. in 1990.PBG acquired Gujarat Themis Biosyn Ltd (GTBL) as a sick company from BIFR in collaboration with Yuhan Corporation, South Korea and became India’s first producer of Rifampicin.Yuhan has provided technology for Rifampicin from fermentation and invested in equity also. Business area of the company
|
||
Company Profile
Gujarat Themis Biosyn Ltd, established in 1981, is a biotech and synthetic product manufacturing company, having plants at Vapi, Hyderabad, with group turnover of over $ 40 million. It has EDMFs, available and WHO approved plants.
The company has world-wide exports to satisfied customers, having customised facility for all products.
The company’s principal activity is to manufacture and distributes pharmaceuticals bulk drugs called rifampicin produced by fermentation process. The company's products include preparations of active pharmaceutical ingredient rifampicin and lovastatin. The company exports its products to Europe and the United States.
Kopran alongwith Cadila Healthcare Ltd., Lyka Labs Ltd., Themis Chemicals Ltd. and Anant & Co., formed Pharmaceutical Business Group (India) Ltd. in 1990.PBG acquired Gujarat Themis Biosyn Ltd (GTBL) as a sick company from BIFR in collaboration with Yuhan Corporation, South Korea and became India’s first producer of Rifampicin.Yuhan has provided technology for Rifampicin from fermentation and invested in equity also.
Business area of the company
| 1 Day |
|
+2.59% |
| 1 Week |
|
-3.55% |
| 1 Month |
|
+27.58% |
| 3 Month |
|
+67.14% |
| 6 Month |
|
+69.99% |
| 1 Year |
|
+121.33% |
| 2 Year |
|
+1093.08% |
| 5 Year |
|
+712.56% |
| 9 years | 2012-03 | 2013-03 | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | |
| Return on Equity (%) | 302.71 | 72.63 | 38.06 | 41.85 | 77.99 | |||||
| Return on Capital Employed (%) | 209.07 | 113.74 | 80.38 | 54.67 | 42.22 | 44.88 | 85.96 | |||
| Return on Assets (%) | 10.56 | 6.02 | 26.54 | 29.88 | 31.50 | 24.25 | 18.45 | 24.07 | 45.62 |
| Particulars | 9 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. |
| Shh. Funds | -14 | -10 | -5 | -1 | 4 | 8 | 12 | 19 | 42 | |
| Non Curr. Liab. | 5 | 7 | 6 | 6 | 2 | 1 | 0 | 1 | 5 | |
| Curr. Liab. | 27 | 21 | 15 | 10 | 9 | 12 | 8 | 13 | 24 | |
| Minority Int. | ||||||||||
| Equity & Liab. | 17 | 18 | 16 | 15 | 15 | 21 | 20 | 33 | 71 | |
| Non Curr. Assets | 13 | 14 | 13 | 11 | 11 | 13 | 13 | 25 | 35 | |
| Curr. Assets | 5 | 4 | 3 | 3 | 3 | 8 | 8 | 8 | 36 | |
| Misc. Exp. not W/O | ||||||||||
| Total Assets | 17 | 18 | 16 | 15 | 15 | 21 | 20 | 33 | 71 |
| Particulars | 9 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. |
| Net Sales | 9 | 28 | 30 | 31 | 33 | 36 | 39 | 41 | 85 | |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | |
| Total Income | 9 | 29 | 30 | 32 | 33 | 36 | 39 | 43 | 87 | |
| Total Expenditure | -11 | -25 | -24 | -25 | -27 | -30 | -33 | -34 | -53 | |
| PBIDT | -2 | 4 | 7 | 6 | 6 | 6 | 6 | 10 | 34 | |
| Interest | -1 | -1 | -1 | 0 | 0 | 0 | 0 | 0 | -1 | |
| Depreciation | -1 | -2 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | |
| Taxation | -1 | -1 | -2 | -8 | ||||||
| Exceptional Items | 6 | |||||||||
| PAT | 2 | 1 | 5 | 5 | 5 | 4 | 4 | 6 | 24 |
| Particulars | 9 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. |
| Cash Fr. Operatn. | 2 | 0 | 4 | 3 | 4 | 3 | 6 | 1 | 1 | |
| Cash Fr. Inv. | -4 | -3 | 0 | 0 | -1 | -3 | -1 | -6 | -3 | |
| Cash Fr. Finan. | 2 | 2 | -3 | -3 | -3 | 0 | -4 | 5 | 2 | |
| Net Change | 0 | 0 | 1 | -1 | 0 | 0 | 1 | 0 | 0 | |
| Cash & Cash Eqvt | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 1 |
|
Fri, 30 Jul 2021
Inter-Se Transfer Of Shares Between The Promoters/ Promoter Group In Accordance With Regulation 10(5) Of SEBI (SAST) Regulations 2011- Signing Of Share Purchase Agreement. We write this in continuation to our letter dated July 24 2021 on the captioned subject. Pursuant to the Regulation 30 and other applicable SEBI Reguations we would like to inform you that the Company has received an information from the Pharmaceutical Business Group (India) Limited one of the promoters that a Share Purchase Agreement has been signed today between Pharmaceutical Business Group(India) Limited and Yuhan Corporation also a Promoter. Please take the same on your records. |
|
Mon, 26 Jul 2021
Revised disclosures under Reg. 10(5) in respect of acquisition under Reg. 10(1)(a) of SEBI (SAST) Regulations 2011 The Exchange has received the revised disclosure under Regulation 10(5) in respect of acquisition under Regulation 10(1)(a) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Pharmaceutical Business Group India Ltd |
|
Mon, 26 Jul 2021
Revised Disclosure Of Inter-Se Transfer Of Shares Between The Promoters/ Promoters Group In Accordance With Regulation 10(5) Of SEBI (SAST) Regulations 2011. We refer to your email dated 26th July 2021 received asking for the revised rectify disclosure under regulation 10(5) of Securities and Exchange Board of India {Substantial Acquisition of Shares and Takeovers) Regulations 2011. In this connection we have received revised rectified disclosure under regulation 10(5) of Securities and Exchange Board of India {Substantial Acquisition of Shares and Takeovers) Regulations 2011 from Pharmaceutical Business Group (India) Limited (Acquirer). We are forwarding herewith the same. Please take the same on record. |
| Mon, 02 Aug 2021 |
Close Crossing Last Month Close from Above
|
Close Within 52 Week High Zone
|
Increasing Relative Strength - Sectoral Index
|
| Fri, 30 Jul 2021 |
High Delivery Percentage
|
|
Close Within 52 Week High Zone
|
Equities
M.F.
Sectors